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Abstract
Background: N-methyl-D-aspartate receptors are one member of a family of ionotropic glutamate receptors that play a pivotal
role in synaptic plasticity processes associated with learning and have become attractive therapeutic targets for diseases
such as depression, anxiety, schizophrenia, and neuropathic pain. NYX-2925 ((2S, 3R)-3-hydroxy-2-((R)-5-isobutyryl-1-oxo2,5-diazaspiro[3.4]octan-2-yl)butanamide) is one member of a spiro-β-lactam-based chemical platform that mimics some
of the dipyrrolidine structural features of rapastinel (formerly GLYX-13: threonine-proline-proline-threonine) and is distinct
from known N-methyl-D-aspartate receptor agonists or antagonists such as D-cycloserine, ketamine, MK-801, kynurenic acid,
or ifenprodil.
Methods: The in vitro and in vivo pharmacological properties of NYX-2925 were examined.
Results: NYX-2925 has a low potential for “off-target” activity, as it did not exhibit any significant affinity for a large panel
of neuroactive receptors, including hERG receptors. NYX-2925 increased MK-801 binding to human N-methyl-D-aspartate
receptor NR2A-D subtypes expressed in HEK cells and enhanced N-methyl-D-aspartate receptor current and long-term
potentiation (LTP) in rat hippocampal slices (100–500 nM). Single dose ex vivo studies showed increased metaplasticity
in a hippocampal LTP paradigm and structural plasticity 24 hours after administration (1 mg/kg p.o.). Significant learning
enhancement in both novel object recognition and positive emotional learning paradigms were observed (0.01–1 mg/kg p.o.),
and these effects were blocked by the N-methyl-D-aspartate receptor antagonist CPP. NYX-2925 does not show any addictive
or sedative/ataxic side effects and has a therapeutic index of >1000. NYX-2925 (1 mg/kg p.o.) has a cerebrospinal fluid half-life
of 1.2 hours with a Cmax of 44 nM at 1 hour.
Conclusions: NYX-2925, like rapastinel, activates an NMDA receptor-mediated synaptic plasticity process and may have
therapeutic potential for a variety of NMDA receptor-mediated central nervous system disorders.
Keywords: NMDA receptor, learning and memory, synaptic plasticity
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Significance Statement

Introduction
N-methyl-D-aspartate (NMDA) receptors are one of a family of
ligand gated ionotropic glutamate receptors that are found predominantly in the CNS and developmentally regulated (CullCandy et al., 2001; Traynelis et al., 2010). They are unique among
glutamate receptors in that they require both glutamate and
glycine for full activation (Danysz and Parsons, 1998). They are
heterotetrameric complexes that are expressed as multiple subtypes each with unique properties (Paoletti et al., 2013). NMDA
receptors play a pivotal role in modulating normal neuronal
functions including activity-dependent synaptic plasticity associated with learning and memory (Bliss and Collingridge, 1993;
Yashiro and Philpot, 2008; Morris, 2013) and have been implicated in a variety of CNS disorders, including schizophrenia
(Coyle, 2012; Goff, 2012), mood disorders (Ghasemi et al., 2014;
Vasilescu et al., 2017), epilepsy (Ghasemi and Schachter, 2011),
neuropathic pain (Millecamps et al., 2007; Zhou et al., 2011),
fibromyalgia (Harris et al., 2008; Pyke et al., 2016), Rett syndrome
(Patrizi et al., 2016), and cognitive decline due to normal aging
(Robb, 1991; Burgdorf et al., 2011a) among others.
Recently, reports have described positive clinical trial
data with mechanistically distinct NMDA receptor modulators including rapastinel (formerly GLYX-13) and ketamine for
depression (Fond et al., 2014; Preskorn et al., 2015) and obsessivecompulsive disorder (Rodriguez et al., 2013, 2016), D-cycloserine
for schizophrenia (Cain et al., 2014) and posttraumatic stress
disorder (de Kleine et al., 2012), and memantine for Alzheimer’s
disease (Wilkinson et al., 2014). The key role that NMDA receptors play in synaptic plasticity throughout the CNS, the marked
increase in NMDA receptor mechanistic studies, including X-ray
crystallographic analysis (Karakas and Furukawa, 2014; Dolino
et al., 2015; Lu et al., 2017), and biophysical studies on receptor subtype properties (Tavoloni and Schaffner, 1989; Iacobucci
and Popescu, 2017), coupled with clinical trial successes seen
with NMDA receptor modulators, make this receptor complex
an attractive target for drug discovery.
Rapastinel is a tetrapeptide (threonine-proline-prolinethreonine) derived from a hypervariable region of a monoclonal
antibody B6B21 (Moskal et al., 2005). B6B21 was shown to act as
a cognitive enhancer (Thompson et al., 1992) with glycine-site
partial agonist properties at the NMDA receptor (Haring et al.,
1991). Rapastinel has also been found to be a robust cognitive
enhancer with marked antidepressant-like effects in a variety of
rat models (Burgdorf et al., 2013, 2017). Mechanistically, rapastinel appears to bind directly to NMDA receptors, triggering an
increase in AMPA receptor activity and leading to a long-term
potentiation-like increase in synaptic plasticity associated with
learning (Moskal et al., 2017).
A key structural feature of rapastinel is its dipyrrolidinebased β-turn motif. A novel chemical platform was created using
spirocyclic-β-lactam chemistry (Bittermann and Gmeiner, 2006)
with a variety of NMDA receptor subtype selectivity, potency,

and activity profiles. NYX-2925 is a representative compound
from this platform. Figure 1 shows the structure of rapastinel
and NYX-2925, and we report on its pharmacological, toxicological, functional, and mechanistic properties.

Materials and Methods
Animals
Adult male Sprague-Dawley rats from Harlan or Charles River
were used for most studies. For the novel object recognition
study, adult male Lister Hooded rats from Harlan were used.
Rats were group housed (3–4 per cage) in Lucite cages with aspen
wood chip bedding, maintained on a 12-hour-light/12-hour-dark
cycle (lights on at 5:00 am), and given ad libitum access to Purina
Lab Chow and tap water throughout the study. For the drug discrimination study, rats were singly housed with ad libitum access
to water. All experiments were approved by the Northwestern
University, Virginia Commonwealth University, and New York
Medical College Institutional Animal Care and Use Committees.

Drugs
NYX-2925 was synthesized by Sai Life Sciences (India) and was
administered p.o. (0.1–10 mg/kg) in 1 mL/kg in 0.5% carboxymethylcellulose (CMC) 0.9% sterile saline. The NMDA receptor
glutamate site antagonist CPP ((±)-3-(2-carboxypiperazin-4-yl)
propyl-1-phosphonic acid) was purchased from Sigma and
administered i.p. (10 mg/kg) in 1 mL/kg 0.9% sterile saline. The
dose of CPP (10 mg/kg i.p.) was chosen based on previous reports
that this dose could block the antidepressant-like effects of an
NMDAR positive modulator without exhibiting behavioral effects
on its own (L. Zhang et al., 2013; Burgdorf et al., 2015b). The
5-HT6 receptor antagonist SB399885 was purchased from GVK
Biosciences (India) and was administered p.o. (10 mg/kg) in 2 mL/
kg 1% CMC and was used as a positive control in the novel object
recognition study (Hirst et al., 2006). Ketamine-HCl (Ketalar) was
obtained from Patterson Veterinary Inc. and was diluted with
0.9 % saline to the concentration required to provide the desired
dose in a 1-mL/kg volume for both i.p. and p.o. administration.

[3H] MK-801 Potentiation Assay
NMDAR Subtype Expressing HEK Cell Membrane Preparation
Crude membranes were prepared using transiently transfected,
NMDAR-expressing HEK cells, described below. All procedures
were performed at 4°C. Briefly, pelleted cells were initially
washed in 10 mM Tris acetate (pH 7.4 at 4°C), pelleted, and frozen at -80°C overnight. The pellet was then resuspended and
homogenized (30 strokes) in a glass homogenizer and pelleted
at 51 500 x g for 30 minutes at 4°C and stored at –80ºC until assay.
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NYX-2925 is a novel NMDA receptor-specific modulator that facilitates synaptic plasticity and has therapeutic potential for a variety of NMDA receptor-mediated central nervous system (CNS) disorders. NYX-2925 was synthesized using a novel spirocyclic-βlactam chemical approach using rapastinel (formerly GLYX-13) as a template, which was in turn synthesized from a hypervariable
region of a unique monoclonal antibody with NMDA receptor modulatory properties. Thus, the creation of NYX-2925 completes
the process of developing monoclonal antibodies to help elucidate the molecular mechanisms of complex biological processes
such as learning and memory and converting them into small molecules with therapeutic potential.

244

|

International Journal of Neuropsychopharmacology, 2018

Functional glycine site agonist effects were measured using
an [3H] MK-801 potentiation assay. Briefly, 300 µg of membrane
extract protein were preincubated for 15 minutes at 25°C in the
presence of a saturating concentration of glutamate (50 µM) and
varying concentrations of NYX-2925. Following the addition of
0.3mCi [3H] MK-801 (Amersham, 22.5 Ci/mmol), reactions were
incubated for an additional 15 minutes (nonequilibrium conditions). Bound and free [3H] MK-801 were separated via rapid
filtration. Zero levels were determined in the absence of any
glycine ligand. The percent maximal [3H] MK-801 binding was
calculated relative to stimulation measured in the presence of
1 mM glycine and 50 µM glutamate. Binding curves were fitted
using GraphPad software.

Creation of the Stable hNMDAR1-Expressing HEK
Cell Line
The cDNA encoding the human GluN1-1 (GenBank BC156961)
was amplified from MGC clone 100063609 using pfu polymerase
and subcloned into the pCMV/zeoDNA3 vector using standard
molecular techniques and verified by direct sequencing. HEK
cells (ATCC) were transfected with the mutant construct using
X-tremeGENE 9 transfection reagent (Roche) and stable clones
selected in Zeocin-containing media.

Creation of the Transient hNMDAR2 (A-D)
Expression Vectors
cDNAs encoding the hNMDAR2A (GENBANK #NM_000833,
pfu polymerase amplified from human cortex cDNA), hNMDAR2B (GENBANK #NM_000834, pfu polymerase amplified
from Open Systems clone #8322670), hNMDAR2C (GENBANK
#NM_000835, pfu polymerase amplified from OriGene clone
#SC300138), and hNMDAR2D (GENBANK #NM_000836, pfu
polymerase amplified from OriGene clone #SC300139) were
subcloned into the pCMV6/XL5 vector using standard molecular techniques.

Off-Target Receptor Binding Assays
To further characterize the target specificity of NYX-2925, we
tested the ability of 10 μM NYX-2925 (>10 000 × Cmax) to compete for binding in a radioligand displacement assay using a
broad panel of known CNS protein targets (LeadProfilingScreen
2, Eurofins Cerep). The binding panel included adenosine
and adrenergic receptor sites; dopamine, histamine, and opioid receptors; calcium channels; and muscarinic cholinergic
receptor sites.

Bioavailability
Male Sprague Dawley rats were dosed with NYX-2925 (1 mg/kg
p.o.), and jugular vein blood draws taken in K2-EDTA-treated
tubes and cisterna magna cerebrospinal fluid (CSF) draws were
taken at various time points. Samples were maintained at 4°C
for 30 to 60 minutes after collection and stored at 80°C until
assay. On the day of the assay, plasma, CSF, and standards were
thawed at 4°C. Samples were extracted with acetonitrile and
NYX-2925 levels were assessed by liquid chromatography tandem mass spectrometry and the lower limit of quantification for
this assay was ~4 nM.

Dendritic Spine Morphology Analysis
Dendritic spine analyses were conducted as previously described
(Ota et al., 2014; Burgdorf et al., 2015b) using the Afraxis ESP
Platform (Afraxis, Inc.). Animals were given a single dose of
NYX-2925 (1 mg/kg p.o.), or 0.5% Na-CMC in 0.9% sterile saline
vehicle (1 mL/kg), and 24 hours post dosing they were deeply
anesthetized (isoflurane) and brains fixed via cardiac perfusion
using 4% paraformaldehyde. Brains were stored in ice cold 0.1
M phosphate buffer and stored at 4°C until sectioning. Brains
were sectioned using a Vibratome (Leica VT1000) to collect sections (300 μm thick) from the anterior to posterior extremes of
each brain. Ballistic dye labeling (DiI and DiO; 3 mg dissolved
in methylene chloride and coated on tungsten particles) was
performed using a commercially available gene gun (Bio-Rad)
to label neurons. Thick sections were mounted to slides with
raised barriers using ProLong Gold (Life Technologies) and cover
slipped. Laser-scanning confocal microscopy (Olympus FV1000)
was performed using a 63 × objective (1.42 NA) to scan individually labeled neurons at high resolution (0.103 × 0.103 × 0.33 μm
voxels). Microscopy was performed blind to experimental conditions. A minimum of 5 cells per animal were sampled. Primary
dendrites within the inner molecular layer were analyzed, and
samples (50 μm) were collected from primary dendrites starting
at 100 μm from the soma. Spine head and neck sizes were analyzed given that larger spine head and necks are associated with
greater NMDAR-mediated calcium flux (Noguchi et al., 2005) as
well as the induction of LTP (Matsuzaki et al., 2004).
Blind deconvolution (AutoQuant) was applied to raw 3‐
dimensional digital images that were then analyzed for spine
density and morphology by trained analysts. Individual spines
were measured manually for (a) head diameter, (b) spine
length, and (c) spine neck diameter from image Z-stacks using
software custom-designed by Afraxis Inc. Each dendrite was
analyzed by 3 to 4 independent analysts. Analysts were blinded
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Figure 1. Structural comparison of the peptide rapastinel with the spirocyclic β-lactam, ((2S, 3R)-3-hydroxy-2-((R)-5-isobutyryl-1-oxo-2,5-diazaspiro[3.4]octan-2-yl)
butanamide) (NYX-2925). Spirocyclic β-lactam chemistry has been used to create a number of new molecules that mimic key properties of their parent peptides
(Bittermann and Gmeiner, 2006).
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to all experimental conditions (including treatment, brain
region, and cell type).

Extracellular Hippocampal Recordings

Hippocampal LTP and LTD Studies
Experiments were conducted as described previously (Zhang
et al., 2008). LTP was induced by 2 theta trains pared by 3 minutes (3 × 100 Hz/500 ms) and LTD induced by a low-frequency
stimulus train (2 Hz/10 min). LTP/LTD was measured 40 minutes
after high- or low-frequency stimulation. NYX-2925 was bath
applied for 40 to 50 minutes starting 20 minutes before application of high- or low-frequency stimulation.
Medial Prefrontal Cortex (MPFC) LTP Studies
Experiments were conducted as described previously (Burgdorf
et al., 2015a). Four-hundred-μm thick slices were cut using a
vibratome (Leica VT1200S) in a modified coronal orientation
(Parent et al., 2010) containing both prelimbic and infralimbic
regions of the MPFC that are targets (via the fornix) of the hippocampal-MPFC pathway. Recording electrodes were inserted
into layer III/IV of the prelimbic MPFC and monosynaptically
evoked fEPSPs evoked by mixed excitatory inputs were recorded
from layer V pyramidal neurons. A bipolar tungsten stimulating
electrode (FHC) was placed on MPFC deep white matter. LTP was
induced by stimulation of input axons with 3 high-frequency
theta burst stimulus trains of 10 × 100 Hz/5 pulse bursts each,
applied at an inter-burst interval of 200 milliseconds. Each train
was 2 seconds in duration, and trains were applied 3 minutes
apart. LTP/LTD was measured 40 minutes after high-frequency

stimulation induction. NYX-2925 was bath applied for 40 to
50 minutes starting 20 minutes before application of high-frequency stimulation.
Metaplasticity Studies
Experiments were conducted as described previously (Burgdorf
et al., 2015b). Rats were dosed with NYX-2925 (1 mg/kg p.o.)
and hippocampal slices were prepared either 24 hours or 1
week post dosing. Three submaximal bouts of high-frequency
Schaffer collateral stimulation (2 × 100 Hz/800 ms) were applied
20 minutes apart. LTP was measured 40 minutes after the last
high-frequency bout of stimulation.

Intracellular Recordings from Hippocampal CA1
Pyramidal Neurons
Whole-cell patch clamp recordings from CA1 pyramidal neurons
were acquired as described previously (Burgdorf et al., 2013).
Patch pipette resistance was 6 to 6.5 MΩ when filled with intracellular solution that contained (in mM): 135 CsMeSO2, 8 NaCl,
10 HEPES, 0.2 EGTA, 2 Mg-ATP, 0.3 Na-GTP, and 1 QX-314 [N-(2,6dimethylphenylcarbamoylthyl)-triethylammonium
bromide],
275 mOsm, pH 7.25 adjusted with Cs(OH)2. CA1 pyramidal neurons were visualized by infrared imaging and patched using a
60x water-immersed objective mounted to a Zeiss microscope
(Axioskop 2 Fs plus). After whole-cell voltage clamp configuration was established, access resistance was carefully monitored,
and only cells with stable access resistance (<5% change) were
included in analyses. Excitatory postsynaptic currents (EPSCs)
were recorded using a MultiClamp 700B (Molecular Devices);
with the low-pass filter setting at 1 to 3 kHz, series resistance
was compensated in the voltage-clamp mode, and patched cells
whose series resistance changed by >10% were rejected from
analysis. Signals were filtered at 3 kHz and digitized at 10 kHz
with a Digidata 1322A controlled by a Clampex (v9.2) (Molecular
Devices). A bipolar tungsten stimulating electrode (FHC) was
placed in the Schaffer collateral-commissural fibers in CA3
stratum radiatum and stimulus pulses (800 µS duration) were
delivered at 15- to 30-second intervals. Neurons were voltage
clamped at -70 mV to record EPSCs to assess input-output relations and paired-pulse facilitation. Neurons were clamped at -40
mV for recording NMDA currents to relieve voltage-dependent
magnesium block, and slices were perfused with ACSF containing 0 added magnesium, 3 mM calcium, 10 µM picrotoxin, and
10 µM CNQX to isolate NMDA conductances.
All recording pipette solutions were made with deionized
distilled water (resistance >18 MΩ cm−2; Milli-Q system). Data
were analyzed initially with Clampfit (v9) (Axon Instruments)
and further processed and presented with Origin 6.1 (Microcal
Software) and CorelDraw 10.0 (Corel) programs.

Novel Object Recognition (NOR)
Experiments were conducted as described previously (Hirst
et al., 2006). Rats were habituated to the NOR test box twice a
day for 2 consecutive days prior to testing. Each habituation session was comprised of a 3-minute exposure to the empty test
box (46 x 30 x 45 cm), followed by 1 minute in the side annex
(1 x 30 x 45 cm) and a further 3 minutes in the test box, thereby
mimicking the test protocol. A vehicle dose was administered
prior to one of the habituation sessions on each habituation day.
The NOR test comprised 2 test sessions, T1 and T2, each lasting 3 minutes. On the first test day, T1, rats were habituated to
the empty test box for 3 minutes and then placed in the side
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Experiments were conducted as described previously (Zhang
et al., 2008; Burgdorf et al., 2015b). Adult male rats were deeply
anesthetized with isoflurane and decapitated. Brains were
removed rapidly, submerged in ice-cold artificial CSF (ACSF,
2–4°C), which contained (in mM): 124 NaCl, 4 KCl, 1.5 MgCl2, 2.5
CaCl2, 1.25 NaH2PO4, 26 NaHCO3, 10 glucose; at pH 7.4, gassed
continuously with 95% O2/5% CO2. Brains were hemisected, the
frontal lobes removed, and individual hemispheres glued using
cyanoacrylate adhesive onto a stage immersed in ice-cold ACSF
gassed continuously with 95% O2/5% CO2 during slicing. Then
400-μm-thick coronal slices were cut using a Vibratome (Leica
VT1200S) and transferred to an interface holding chamber for
incubation at room temperature for a minimum of 1 hour before transferring to a Haas-style interface recording chamber
continuously perfused at 3 mL/min with oxygenated ACSF at
32 ± 0.5°C.
Low resistance recording electrodes were made from thinwalled borosilicate glass (1–2 MΩ after filling with ACSF) and
inserted into the apical dendritic region of the Schaffer collateral termination field in stratum radiatum of the CA1 region
to record field excitatory postsynaptic potentials (fEPSPs). A bipolar stainless-steel stimulating electrode (FHC) was placed on
Schaffer collateral-commissural fibers in CA3 stratum radiatum,
and constant current stimulus intensity adjusted to evoke approximately half-maximal fEPSPs once each 30 seconds (50–100
pA; 100-μs duration). fEPSP slope was measured before and after
induction of LTP or LTD by linear interpolation from 20% to 80%
of maximum negative deflection, and slopes confirmed to be
stable to within ± 10% for at least 15 minutes before commencing
an experiment. Signals were recorded using a Multiclamp 700B
amplifier and digitized with a Digidata 1322 (Axon Instruments).
Data were analyzed using pClamp software (version 9, Axon
Instruments).
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Ultrasonic Vocalization (USV) Assay
Heterospecific rough-and-tumble play was conducted as previously described (Burgdorf et al., 2011b). The experimenter
was blind to the treatment condition of the animals. Animals
received 3 minutes of heterospecific rough-and-tumble play
consisting of alternating 15-second blocks of heterospecific
play and 15 seconds of no stimulation. High-frequency USVs
were recorded and analyzed by sonogram in a blind manner
as described previously (Burgdorf et al., 2011b). At the end of
the 3-minute session, the latency for the rat to approach the
experimenters hand to self-administer heterospecific play was
also measured. Animals were not habituated to play stimulation before dosing and testing. Using this paradigm, the increase in 50-kHz USVs that occurs across trial blocks reflects
positive emotional learning (Burgdorf et al., 2011b; Ishiyama
and Brecht, 2016).
Animals were administered NYX-2925 (1 mg/kg p.o.) or CMC
saline (p.o.) 1 hour before testing. Rats received the NMDA receptor glutamate site antagonist CPP (10 mg/kg i.p.) or sterile
saline (i.p.) 2 hours before NYX-2925 (1 mg/kg p.o.) or CMC saline (p.o.). This dose of NYX-2925 was chosen given that it leads
to CSF exposures that activate all 4 NMDAR subtypes (Figures
2A-D and 4A) and showed maximal facilitation of learning and
memory in the novel object recognition test (Figure 5A).

minutes using a within-subjects design. Habituation and testing consisted of placing rats onto the fixed speed version of the
Rota-Rod test (16 RPM) for 300 seconds, and the latency to fall off
the Rota-Rod was recorded.

Open Field Test of Locomotor Activity
Open field testing was conducted as previously described
(Burgdorf et al., 2013). Rats were placed into the center chamber of
the open field (40 x 40 x 20 cm) for 10 minutes under dim-red lighting 1 hour post dosing with NYX-2925 (1 mg/kg p.o.) or vehicle
(1 mL/kg p.o.). Line crosses were scored offline from video recordings by an experimenter blinded to the treatment condition.

Drug Discrimination
Testing was conducted as described previously (Burgdorf
et al., 2013). Adult male Sprague-Dawley rats were trained to
discriminate ketamine (5.6 mg/kg, i.p.) from saline (1 mL/kg, i.p.)
5 d/wk (Monday-Friday; 15 min/d) in standard 2-lever operant
conditioning chambers (Med Associates) under a double-alternation schedule of ketamine or saline (K, K, S, S, K, K, etc.). Rats
were placed in the operant conditioning chamber 10 minutes
post-injection and the session initiated as signaled by illumination of the chamber house light. Completion of 10 consecutive
responses (fixed ratio 10; FR 10) on the correct lever resulted in
delivery of a 45-mg food pellet (Bio-Serv) and illumination of a
white stimulus light over the lever. Incorrect responding reset
the FR for correct-lever responding. Food (Harlan Teklad Rodent
Diet) access beyond those obtained during behavioral sessions was restricted to ~20 g given post session. Animals were
tested following administration of various doses of NYX-2925
(1, 10, 100 mg/kg, p.o.), CMC saline (2 mL/kg) or ketamine (10, 17
30 mg/kg, p.o.), and lever selection and rates of responding were
recorded. Doses of NYX-2925 and its vehicle were administered
1 hour prior to the session start and p.o. ketamine was administered 15 minutes prior to session start. For all p.o. test sessions,
rats were also administered i.p. saline, 1 mL/kg, 10 minutes prior
to session start to mimic training conditions. Training continued under the double alternation of 5.6 mg/kg ketamine and
saline injections between test sessions. Illumination of lights,
recording of responses, and pellet delivery were performed with
MED-PC operant conditioning software (version 1.1).

Statistical Analysis
Behavioral and electrophysiological data were analyzed by
ANOVA, followed by Fisher’s PLSD posthoc test (Statview). The
level of statistical significance was set at P < .05.
Data from the [3H] MK-801 potentiation assay data was analyzed by Prism (Graphpad).

Results

Rota-Rod Test of Motor Coordination

[3H] MK-801 Potentiation and Off-target Receptor
Binding

Rota-Rod testing was conducted as previously described
(Nadeson et al., 2002) using a 4-station Rota-Rod apparatus (Med
Associates). One day before testing, animals received 3 Rota-Rod
habituation sessions with at least 30 minutes between each session and an additional habituation session immediately before
dosing (0 min). Animals were dosed with NYX-2925 (1–100 mg/
kg p.o.) or CMC saline. Animals were tested 15, 30, 60, and 120

NYX-2925 facilitated [3H] MK-801 binding in all four human
NMDAR2 subtypes. The concentration-response curves for NYX2925 assessed in hNR1-expressing HEK cells transfected with
hNR2A, 2B, 2C, and 2D are shown in Figure 2. The activity of NYX2925 was 40.6%, 47.1%, 63.1%, and 57.8% of [3H] MK-801 activity
measured in the presence of maximal glycine for hNR2A, 2B, 2C,
and 2D receptors, respectively. The potency (EC50) of NYX-2925
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annex for approximately 1 minute whilst 2 identical test objects
were placed in the test arena equally spaced to each other and
the side walls. The rat was then returned to the test arena and
allowed to freely explore the objects for a further 3 minutes. At
the end of the test session, the rat was returned to its home
cage. Following a 24-hour inter-trial interval, the recall trial (T2)
was conducted. T2 was similar to T1 except that one of the “familiar” objects was substituted for a novel one of a similar size
and color but different shape. The objects used were made of
black hardened plastic and were geometric shapes (towers and
pyramids) that were of no relevance to the animals. Objects were
cleaned between trials with 70% ethanol to eliminate odor cues.
T1 and T2 trials were recorded by GeoVision surveillance
camera software and files were saved on DVD for remote scoring by an operator blinded to the treatments. Exploration was
scored as time spent sniffing or licking the objects, when the
nose was in contact with the object and was moving (i.e., when
the animal was sniffing). Sitting on the object or next to it with
the nose directed away was not classed as exploration. The discrimination index [(time spent exploring the novel object - time
spent exploring the familiar object)/total exploration time] was
then calculated for T2.
For the NYX-2925 groups, 0.01, 0.1, or 1 mg/kg p.o. was
administered 60 minutes before T1 and CMC saline administered 1 hour before T2. For the SB399885 group, 10 mg/kg p.o.
was administered 240 minutes before both T1 and T2. For the vehicle group, CMC saline (1 mL/kg) was administered 60 minutes
before both T1 and T2.
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was 55 pM, 28 fM, 11 pM, and 55 pM for hNR2A, 2B, 2C, and 2D
receptors, respectively.
NYX-2925 (10 µM) did not exhibit any significant affinity (considered >50%) for any of the 81 binding sites tested (Table 1). At 10
μM, NYX-2925 did not demonstrate significant inhibition or stimulation (agonism) in any of the 81 sites. This study provides evidence that NYX-2925 has a low potential for “off-target” activity.

NMDAR Current and Long-Term Potentiation in
Hippocampus and Medial Prefrontal Cortex
NYX-2925 (100–500 nM) increased the magnitude of pharmacologically isolated NMDA current in Schaffer collateral-evoked
EPSCs in CA1 pyramidal neurons (repeated-measures ANOVA
F(3,18) = 7.2, P < .05; within-subjects t test vs baseline NYX-2925
[100 and 500 nM] vs vehicle, P < .05; Figure 3A). NYX-2925 also
increased the magnitude of LTP at Schaffer collateral-CA1 synapses (F(4,30) = 6.2, P < .05; Fisher’s PLSD posthoc test NYX-2925 [500
nM] vs vehicle, P < .05; Figure 3B) and inhibited LTD at these same
synapses (F(3,28) = 4.1, P < .05; Fisher’s PLSD posthoc test NYX-2925

[5000 nM] vs vehicle, P < .05; Figure 3C). Moreover, LTP at mixed
excitatory inputs synapsing in layer II/III of MPFC was also facilitated by NYX-2925 (F(4,27) = 5.6, P < .05; Fisher’s PLSD posthoc test
NYX-2925 [100 and 500 nM] vs vehicle, P < .05; Figure 3D).

Pharmacokinetics and Toxicology
NYX-2925 showed high oral bioavailability, CNS penetration, and
had a wide therapeutic index. As shown in Figure 4A, NYX-2925
(1 mg/kg p.o.) has a plasma Cmax of 706 nM at 1 hour, a plasma
half-life of 6.8 hours, a CSF Cmax of 44 nM at 1 hour, and a CSF
half-life of 1.2 hours. The Cmax CSF exposure is 44 nM. The oral
bioavailability of NYX-2925 in plasma is 56% as calculated by the
area under the curve of plasma exposure following 2 mg/kg i.v.
or 10 mg/kg p.o. dosing (mean ± SEM AUC IV 2155.12 ± 45.77, p.o.
6053.73 ± 498.55 ng.h/mL).
The no observed adverse effect level of NYX-2925 for male
Sprague Dawley rats when administered by the oral (gavage)
route, once daily for 14 consecutive days is 1000 mg/kg/d as
measured by mortality, clinical signs, body weight, food intake,
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Figure 2.NYX-2925 is active at all 4 human N-methyl-D-aspartate receptor (hNMDAR) 2 subtypes. Potentiation of [3H] MK-801 binding by NYX-2925 and glycine in hNMDAR subtype-expressing human embryonic kidney (HEK) cells. Stable hNMDAR1-expressing HEK cells were transiently transfected with cDNAs encoding hNMDAR2A,
hNMDAR2B, hNMDAR2C, or hNMDAR2D. At 48 hours post-transfection, membrane-bound receptors were isolated, and the functional glycine site agonist effects were
measured using the [3H] MK-801 potentiation assay, as described in Methods. The percent maximal effects were calculated relative to stimulation in the presence of 1
mM glycine and 50 μM glutamate. Binding curves were fitted using GraphPad Prism software.
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Table 1. Radioligand Displacement by NYX-2925 (10 μM)
NYX-2925
% Inhibition

A1 (antagonist)
A2A (agonist)
A3 (agonist)
α1 non-selective (antagonist)
α2 non-selective (antagonist)
β1 (agonist)
β2 (agonist)
AT1 (antagonist)
AT2 (agonist)
BZD central (agonist)
BZD peripheral (antagonist)
BB non-selective (agonist)
B2 (agonist)
CGRP (agonist)
CB1 (agonist)
CCK1 CCKA (agonist)
CCK2 CCKB (agonist)
D1 (antagonist)
D2S (antagonist)
D3 (antagonist)
D4.4 (antagonist)
D5 (antagonist)
ETA (agonist)
ETB (agonist)
GABA non-selective (agonist)
GAL1 (agonist)
GAL2 (agonist)
PDGF (agonist)
CXCR2 IL-8B (agonist)
CCR1 (agonist)
TNF-α (agonist)
H1 (antagonist)
H2 (antagonist)
MC4 (agonist)
MT1 ML1A (agonist)
M1 (antagonist)
M2 (antagonist)
M3 (antagonist)
M4 (antagonist)
M5 (antagonist)
NK1 (agonist)
NK2 (agonist)
NK3 (antagonist)
Y1 (agonist)
Y2 (agonist)
NTS1 / NT1 (agonist)
δ2 (DOP) (agonist)
κ (KOP) (agonist)
μ (MOP) (agonist)
NOP / ORL1 (agonist)
PAC1 / PACAP (agonist)
PPARγ (agonist)
PCP (antagonist)
EP2 (agonist)
EP4 (agonist)
IP PGI2 (agonist)
P2X (agonist)
P2Y (agonist)
5-HT1A (agonist)
5-HT1B (antagonist)
5-HT2A (antagonist)
5-HT2B (agonist)

-4.2
-6.1
-4.9
-10
-11.6
4.6
-7.6
-0.8
1.8
-9.1
-6.6
-9
-3.1
3.6
5.7
3.8
-13
-19.9
6.8
-5.2
-5
4.1
5.7
1.3
-18.8
3
3.7
-2.6
-4.5
0
-21.7
2.4
0.5
3.4
1.4
-23.4
-6.1
-10.1
-11.3
5.6
-22.5
2.4
-7.7
-3.4
-9.9
-11.4
-4.2
0.1
-4.5
5.9
-4.4
-10.7
-5.7
4.7
7.5
-5.1
16.1
5.1
2.5
-6.7
-5.8
2.1

Site

NYX-2925
% Inhibition

5-HT2C (antagonist)
5-HT3 (antagonist)
5-HT5a (agonist)
5-HT6 (agonist)
5-HT7 (agonist)
Sigma (non-selective) (agonist)
SSST (non-selective) (agonist)
GR (agonist)
VPAC1 (VIP1) (agonist)
V1 a (agonist)
Verapamil site (antagonist)
hERG [3H] Dofetilide
KV channel (antagonist)
SKCa channel (antagonist)
Na+ channel (site 2) (antagonist)
Cl- channel GABA-gated (antagonist)
Norepinephrine transporter (antagonist)
Dopamine transporter (antagonist)
5-HT transporter (antagonist)

-5.9
2.7
-7.5
-8.6
-5.1
-15.8
-13.8
-6.2
7.4
15.3
3.4
-3
-7.4
5
7.3
5.2
-6.2
-6.4
-13.9

Results that show an inhibition or stimulation >50%
are considered to represent significant effects of the test compound.

and gross histopathology as well as organ weights. The plasma
exposure (area under the curve) of NYX-2925 following 14 daily
doses of 1000 mg/kg was 1 074 478 ng.h/mL compared with
494 ng.h/mL for a single behaviorally efficacious dose of 1 mg/
kg, thus resulting in a projected therapeutic index of 2175.

Structural Plasticity
NYX-2925 (1 mg/kg p.o.; 24 hours post dosing) induced structural plasticity as indexed by increased diameter of spine heads
(F(1,3441) = 44.2, P < .05) and necks (F(1,3441) = 27.2, P < .05) in the primary apical dendrites of dentate granule neurons (Figure 4B).
Spine length (F(1,3441) = 2.9, P > .05) or total spine number (F(1,65) = 1.1,
P > .05) was not affected by NYX-2925 (Figure 4B).

Metaplasticity
NYX-2925 persistently enhanced LTP at 24 hours and 1 week
following a single dose (1 mg/kg p.o.) at Schaffer collateral-CA1
synapses after 3 submaximal high-frequency stimulus trains
(2 × 100 Hz/800 ms, arrows). LTP was evaluated either 24 hours
post dosing (F(1,13) = 5.5, P < .05) or 1 week post dosing (F(1,14) = 8.8,
P < .05) as shown in Figure 4C-D.

Learning and Memory Tests
NYX-2925 facilitated learning and memory in multiple paradigms across a wide dose range. NYX-2925 (0.01, 0.1, 1 mg/kg
p.o.), delivered 1 hour prior to T1, increased novel object recognition after a 24-hour delay between training and testing to
a similar degree as the positive control SB399885, delivered 4
hours prior to T1 and T2 (F(4,54) = 11.5, P < .05; Fisher’s PLSD posthoc test NYX-2925 [0.01, 0.1, 1 mg/kg] or SB399885 vs vehicle,
P < .05; Figure 5A).
NYX-2925 (1 mg/kg p.o.) facilitated positive emotional
learning and this effect was blocked by pretreatment with
a single dose of the NMDAR antagonist CPP as measured by
both increased rates of hedonic 50-kHz USVs across trials
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Figure 3. NYX-2925 facilitates NMDA current and NMDA receptor-dependent LTP, while decreasing LTD. (A) NYX-2925 (0.1–0.5 µM) enhanced the pharmacologicallyisolated NMDAR current in Schaffer collateral-evoked EPSCs in hippocampal CA1 pyramidal neurons. NYX-2925 (B) enhanced the magnitude of LTP at 0.5 µM and (C)
decreased the magnitude of LTD at 5 µM of synaptic transmission at Schaffer collateral-CA1 synapses as compared to untreated control (aCSF) slices. (D) NYX-2925 (0.1
and 0.5 µM) enhanced the magnitude of LTP in layer II/III-evoked normalized field EPSP slopes in rat slices recorded in MPFC layer IV. NYX-2925 was bath applied for
40–50 min starting 20 min before high-frequency theta trains to induce LTP (solid bar) or low-frequency stimulation to elicit LTD (solid bar). LTP/LTD was measured 40
min after high- or low-frequency stimulation. Data are shown as mean ± SEM. N = 7 cells per group (A) or 5–10 slices per group (B-D). * P < .05, (A) within-subjects t test
vs baseline (B-D) Fishers PLSD post hoc test vs vehicle.
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(repeated-measures ANOVA: dosing group F(3,31) = 37.7, P < .05;
trials F(5,31) = 39.8, P < .05, dosing group x trials F(15,31) = 15.0,
P < .05, Fisher’s PLSD posthoc test NYX-2925 alone vs all other
groups, P < .05; Figure 5B) and increased running speed to selfadminister heterospecific rough-and-tumble play (F(3,31) = 12.6,
P < .05; Fisher’s PLSD posthoc test NYX-2925 alone vs all other
groups, P < .05; Figure 5C). In addition, NYX-2925 (0.001–1 mg/
kg p.o.) increased positive emotional learning 1 hour post dosing (F(5,53) = 4.6, P < .05, Fisher’s PLSD posthoc test 0.001, 0.01, 0.1,
1 mg/kg vs vehicle, P < .05; data not shown).

Safety Pharmacology
NYX-2925 did no induce sedation/ataxia and does not show
ketamine-like drug discrimination. NYX-2925 (1–100 mg/kg
p.o.) did not induce a sedative/ataxic effect in the Rota-Rod test
(F(3,29) = 0.5, P > .05; Figure 6A) or alter locomotor activity in the
open field test at 1 mg/kg p.o. (F(1,22) = 0.002, P > .05; Figure 6B).
Ketamine (p.o.), but not NYX-2925, substituted for a training
dose of ketamine (5.6 mg/kg i.p.) in a dose-dependent manner in the

drug discrimination task (F(6,36) = 90.9, P < .05; Fisher’s PLSD posthoc
test ketamine [17 and 30 mg/kg p.o.] vs vehicle, P < .05; Figure 6C).
Unlike ketamine, NYX-2925 did not suppress operant responding
at the highest dose tested (F(6,36) = 9.1, P < .05; Fisher’s PLSD post hoc
test ketamine [30 mg/kg p.o.] vs vehicle, P < .05; Figure 6D)).

Discussion
The NMDA receptor has recently become an attractive target for
the development of therapeutics for the treatment of a variety of
CNS disorders. Clinical trial data have shown that NMDA receptor
modulators have efficacy in mood disorders such as depression,
obsessive compulsive disorder, schizophrenia, as well as in neuropathic pain, among others (Rodriguez et al., 2013; Cain et al., 2014;
Feder et al., 2014; Fond et al., 2014; Maher et al., 2017). To date, only
rapastinel and DCS have shown efficacy in clinical trials without
the side effects seen with NMDA receptor antagonists. DCS has
shown a comparatively weak therapeutic response profile and
results have been mixed (Laake and Oeksengaard, 2002; Tuominen
et al., 2005; Ori et al., 2015). Rapastinel is a peptide that must be
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Figure 4. NYX-2925 persistently enhances hippocampal structural plasticity and metaplasticity following a single in vivo dose (1 mg/kg PO). (A) Plasma and CSF levels
following dosing with NYX-2925 (1 mg/kg PO) were measured by LC/MS/MS. The Cmax in the CSF is 44 nM (at 30 min post-dosing) which is well above the threshold for
activing NR2A-D receptors (1 nM) as shown in Figure 2. A single in vivo dose of NYX-2925 (1 mg/kg PO) increased (B) spine head and neck diameter in hippocampal
dentate gyrus primary dendrites 24 hrs post-dosing, and (C,D) the magnitude of LTP compared to slices from vehicle-treated control rats prepared (C) 24 hrs and (D) 1
week post-dosing (NYX-2925, 1 mg/kg PO) at Schaffer collateral-CA1 synapses after 3 sub-maximal high-frequency stimulus trains (2 × 100 Hz/800 ms, arrows). Data are
shown as Mean ± SEM. N = (A) 2–3 rats, (B) 1412–2034 spines, and (C-D) 6–8 slices per group.
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Figure 6. NYX-2925 does not produce ketamine-like sedative/ataxic or discriminative stimulus effects. (A) NYX-2925 (1, 10, 100 mg/kg PO) did not produce sedation/
ataxia in the fixed speed (16 RPM) RotaRod test. (B) Locomotor activity in the open field was not altered by NYX-2925 (1 mg/kg PO). (C,D) NYX-2925 does not substitute
for ketamine as measured by (C) percentage ketamine-lever responding and (D) rates of responding for ketamine (10, 17, 30 mg/kg PO) and NYX-2925 (1, 10, 100 mg/kg
PO) in rats trained to discriminate 5.6 mg/kg ketamine from saline. N = 6–12 per group. * Fisher’s PLSD post hoc test vs vehicle.
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Figure 5. NYX-2925 facilitates learning and memory by activating NMDA receptors. (A) NYX-2925 (0.1–1 mg/kg PO, delivered 1 h prior to training) facilitated novel object
recognition as measured by the D2 index [(novel object exploration time – familiar object exploration time) / total exploration time in T2)] tested 24 hrs after training.
Pretreatment with a silent dose of the NMDA receptor antagonist CPP blocked the facilitation of learning in the positive emotional learning assay seen with NYX-2925
tested 1 hr after NYX-2925 administration (1 mg/kg PO) as measured by (B) increased rates of hedonic 50-kHz USVs across trial blocks and (C) increased running speed
to self-administer heterospecific rough-and-tumble play. Data are shown as mean ± SEM. N = rats 8–12 per group. * P < .05, Fishers PLSD post hoc test (A) vs vehicle or
(B) vs all other groups.
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The data reported here show that NYX-2925 is an NMDAR
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MPFC, and reduce while actually reducing LTD in hippocampus.
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(Abraham and Bear, 1996). NYX-2925 is orally bioavailable and does
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in toxicology studies, suggesting a wide therapeutic index (>1000).
Alonso et al. (2001) showed that spirocyclic β-lactams could
be synthesized with β -turn conformations making the creation
of peptidomimetics using conventional peptide chemistry techniques possible, and Bittermann and Gmeiner (2006) reported the
synthetic methods for β-turn-containing spirocyclic-β-lactams
starting from natural proline. Recently, this approach has been
used to develop peptidomimetics of the dopamine receptor modulating peptide L-prolyl-L-leucyl-glycinamide (Khalil et al., 1999)
and the creation of somatostatin mimetics (Lesma et al., 2013).
Using a similar chemical synthesis approach, we have been able
to create a novel platform of rapastinel mimetics, exemplified by
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function. And since NYX 2925 appears to be an excellent therapeutic candidate, other compounds from this platform may lead
to additional NMDAR modulators with therapeutic potential.
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